Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 10/20 | 0.41 |
| ▸ | KDR | P35968 | 10/20 | 0.41 |
| ▸ | KIT | P10721 | 8/20 | 0.41 |
| ▸ | FLT3 | P36888 | 6/20 | 0.41 |
| ▸ | RET | P07949 | 3/20 | 0.41 |
| ▸ | FLT4 | P35916 | 3/20 | 0.41 |
| ▸ | FLT1 | P17948 | 2/20 | 0.41 |
| ▸ | TOP1 | P11387 | 2/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | CASP3 | P42574 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | PLK4 | O00444 | 2/20 | 0.34 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.34 |
| ▸ | DAPK3 | O43293 | 2/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.34 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.34 |
| ▸ | RPS6KA4 | O75676 | 2/20 | 0.34 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305329 | 1.00 | PDGFRB (0.41) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4300909 | 0.93 | PDGFRB (0.42) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4300907 | 0.93 | PDGFRB (0.42) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4303535 | 0.92 | KDR (0.38) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4303537 | 0.92 | KDR (0.38) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4301856 | 0.91 | KDR (0.43) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4301853 | 0.91 | KDR (0.43) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4308617 | 0.90 | KDR (0.41) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4308613 | 0.90 | KDR (0.41) | PDGFRBKDRKITFLT3RET | |
| SCHEMBL4308610 | 0.88 | NTRK1 (0.39) | PDGFRBKDRTOP1MAOBNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-20130267497-A1 | KINASE INHIBITORS | ALLERGAN INC (US) | 2013-10-10 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455656-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| US-20120238558-A9 | Kinase inhibitors | ALLERGAN, INC. | 2012-09-20 | — | — | US | disclosed |
| WO-2010099368-A1 | OCULAR IMPLANTS COMPRISING KINASE INHIBITORS | ALLERGAN, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20090286773-A1 | Kinase inhibitors | ALLERGAN, INC. | 2009-11-19 | — | — | US | disclosed |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | ALLERGAN, INC. | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267497-A1 | KINASE INHIBITORS | PTK2, MAP3K6, MAP3K20 | PDGFRB 368/4885KDR 51/4885KIT 339/4885 |
| US-20090286773-A1 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | PDGFRB 368/4885KDR 51/4885KIT 339/4885 |
| US-20060004084-A1 | (3Z)-3-(2,3-dihydro-1H-inden-1-ylidene)-1,3-dihydro-2H-indol-2-ones as kinase inhibitors | CDK2, ERBB2, MAP3K3 | PDGFRB 502/4885KDR 320/4885KIT 683/4885 |
| US-20120238558-A9 | Kinase inhibitors | PTK2, MAP3K6, MAP3K20 | PDGFRB 368/4885KDR 51/4885KIT 339/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.